BLT offers a potential curative treatment for Hep C at $150 mill MC and 3 other programs around the preclinical stages. Gilead offers a potential curative treatment at $128 billion and paid 11 billion for the tech. Even if the outcomes from both treatments are on par, the Fed/medical insurance companies doing the reimbursing for treatment would have a massive advantage in the vastly cheaper option of BLT. The other element is that success in this program would validate BLT's tech and open a plethora of new opportunities for this little company.
- Forums
- ASX - By Stock
- BLT
- old myth of curing hepc with antisense
old myth of curing hepc with antisense, page-25
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)